Physician profile
Veronica Ortiz
NPI 1679867352
$829.04
in general payments reported to CMS, 2019-2025
11 companies · $301 in 2025
The $301 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $136 · 2022: $41.50 · 2023: $41.42 · 2024: $310 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $300.76 | 2022-2025 | |
| Thd America, INC. | $95.98 | 2021 | |
| Gilead Sciences, INC. | $77.06 | 2025 | |
| Astellas Pharma US INC | $70.00 | 2024 | Veozah |
| Dynavax Technologies Corporation | $59.23 | 2024-2025 | Heplisav-B |
| Exact Sciences Corporation | $55.81 | 2024-2025 | Cologuard Collection Kit |
| Shield Therapeutics INC | $44.33 | 2024-2025 | |
| Viiv Healthcare Company | $41.27 | 2024 | Apretude |
| Lilly USA, LLC | $35.32 | 2021-2024 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $24.86 | 2024 | Eliquis |
| Dendreon Pharmaceuticals LLC | $24.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Ortiz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.